Developer docs
API playgroundTry for free, no card

Search company profiles

GeneCode AS

Full company profile

uuid0003j67

Namestring
GeneCode AS
Legal namestring
GeneCode Ltd.
Websiteurl
genecode.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

GeneCode AS (legal entity GeneCode Ltd.) is an Estonian preclinical-stage pharmaceutical company headquartered in Tallinn that develops small-molecule drugs designed to activate the GDNF (Glial cell line-Derived Neurotrophic Factor) receptor complex (GFRα1/RET) and thereby protect or restore neurons in neurodegenerative and related diseases. Its science originated in Prof. Mart Saarma's laboratory at the University of Helsinki, where the crystal structure of the GDNF/GFRα1 receptor complex was solved, enabling rational small-molecule design; a proprietary high-throughput luciferase assay was then used to screen over 30,000 compounds from the company's chemical library, yielding lead candidates (including BT13) reported to be more potent than natural GDNF and capable of crossing the blood-brain barrier for oral systemic delivery.

The product portfolio currently comprises a GDNF Mimetics Platform and four indication-targeted drug candidate programs: RET agonists for Parkinson's disease (the primary lead), GDNF mimetics for amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, and inflammatory bowel disease (IBD). Parkinson's disease is the most advanced program, targeting both motor and non-motor symptoms via weekly or less-frequent oral dosing and designed as the first disease-modifying rather than symptomatic therapy. The IP base includes 50+ patent families, and the underlying research is supported by 600+ peer-reviewed publications with 30,000+ citations.

GeneCode generates no commercial product revenue today; its economics rest on non-dilutive grant funding (Enterprise Estonia, Estonian Business and Innovation Agency, EU Regional Development Fund) plus a single €14.3M equity tranche inside the €16M EIC Accelerator award received in 2023. Its go-to-market is event- and partnership-driven — Argobio co-develops the Kevad Bio Parkinson's project, and the company participates in EU forums such as Healthcare Transformation Forum and Medtech Impact 2025 — with the explicit commercial endpoint being licensing or co-development agreements with major pharmaceutical companies for clinical development, regulatory approval, and global commercialization of disease-modifying therapies in Parkinson's disease, ALS, IBD, and retinitis pigmentosa.

Short descriptiontext

GeneCode AS is an Estonian preclinical-stage pharmaceutical company developing orally bioavailable small-molecule GDNF mimetics for Parkinson's disease, ALS, inflammatory bowel disease, and retinitis pigmentosa. The platform pursues disease-modifying therapies via GFRα1/RET receptor agonism, funded through EU and Estonian grants and targeting future pharma licensing agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTallinn, Estonia
HQ citystring
Tallinn
HQ countrystring
Estonia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule drugs, neurodegenerative disease therapeutics, GDNF receptor agonists, pharmaceutical R&D, disease-modifying therapies
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurodegenerative Disease Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Drug Development and Licensing
TypeLicensing Royalties
Description

As a preclinical-stage pharmaceutical company, GeneCode is developing small-molecule drugs for neurodegenerative diseases. Revenue will be generated through licensing agreements, co-development partnerships with pharmaceutical companies, and eventual product sales following regulatory approval. The company has received significant grant and equity funding from EU and Estonian sources to advance clinical development.

genecode.com
2Government Grants and Non-dilutive Funding
TypeManaged Services
Description

GeneCode has secured multiple grants including €16M from EIC Accelerator (split as €1.7M grant and €14.3M equity), €1.5M from Estonian Business and Innovation Agency, €1.6M from Enterprise Estonia, and €2M R&D Grant from Enterprise Estonia. These grants support preclinical research and IND-enabling studies.

estonianworld.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GeneCode AS is a preclinical-stage pharmaceutical company developing small-molecule drugs that activate GDNF receptors (GFRα1/RET complex) to protect and restore neurons. Its lead program targets disease-modifying treatment of Parkinson's disease via orally bioavailable RET agonists that cross the blood-brain barrier, with additional programs in ALS, inflammatory bowel disease, and retinitis pigmentosa. The company leverages a proprietary GDNF Mimetics Platform built on the resolved crystal structure of the GDNF/GFRα1 receptor complex and high-throughput screening of 30,000+ compounds.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Neuroprotective effects demonstrated in both animal models of Parkinson's disease and laboratory models using human dopamine neurons
+2 more records
Product overview1 text field

GeneCode is a preclinical-stage pharmaceutical company developing a GDNF Mimetics Platform that enables the discovery and development of small molecule drugs targeting GDNF (glial cell line-derived neurotrophic factor) receptors. The company's lead program focuses on RET agonists for Parkinson's disease treatment, with the platform also being applied to develop candidates for ALS, retinitis pigmentosa, and inflammatory bowel disease. The GDNF Mimetics Platform was used to screen over 30,000 compounds, identifying lead candidates now advancing into IND-enabling studies. Key drug candidates include BT13, a novel small molecule GDNF receptor RET agonist.

Product and service6 records
1GDNF Mimetics Platform
CategoryDrug discovery platform
Description

Proprietary drug discovery platform that identifies and develops small molecule compounds activating GDNF receptors (GFRα1/RET complex) to mimic neurotrophic factor activity for treatment of neurodegenerative diseases. Built on the resolved GDNF/GFRα1 receptor crystal structure and a high-throughput luciferase assay screening 30,000+ compounds; for internal pipeline use and partnership with pharmaceutical companies.

2RET Agonists for Parkinson's Disease
CategoryDrug candidate
Description

Small molecule RET receptor agonists targeting the GFRα1-RET complex for disease-modifying treatment of Parkinson's disease, designed to cross the blood-brain barrier and be administered orally, addressing both motor and non-motor symptoms.

3GDNF Mimetics for ALS
CategoryDrug candidate
Description

Small molecule GDNF receptor agonist drug candidates being developed as a neuroprotective therapy for amyotrophic lateral sclerosis (ALS), targeting motor neuron survival.

4GDNF Mimetics for Retinitis Pigmentosa
CategoryDrug candidate
Description

GDNF receptor agonist compounds being explored as a neuroprotective therapy for retinitis pigmentosa, targeting progressive dysfunction of retinal rod and cone photoreceptor cells.

5GDNF Mimetics for Inflammatory Bowel Disease
CategoryDrug candidate
Description

GDNF receptor agonist compounds being explored for treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis), targeting intestinal epithelium barrier dysfunction.

6BT13 Compound
CategoryDrug candidate
Description

Novel small molecule GDNF receptor RET agonist discovered by GeneCode, shown to promote neurite growth from sensory neurons and demonstrating neuroprotective effects in Parkinson's disease models.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-01
Description

GeneCode partnered with Argobio on Parkinson's Disease research in Argobio's first announced research agreement. The collaboration focuses on the Kevad Bio project developing GDNF mimetics for Parkinson's disease treatment. Argobio is a biotech studio that provides operational support and resources for early-stage biotech companies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

GeneCode collaborates with the Institute of Biotechnology, HiLIFE, University of Helsinki where Prof. Dr. Mart Saarma serves as research director and professor. The collaboration provides access to cutting-edge neuroscience research and facilities for neurotrophic factor studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Finnish clinical-stage biotech developing CDNF (cerebral dopamine neurotrophic factor) protein therapy for Parkinson's disease — directly comparable given GeneCode's co-founder Prof. Saarma's relationship to CDNF and the overlapping neurotrophic factor / Parkinson's disease-modifying mechanism.

TypeRegional player
Description

Swedish biotech developing disease-modifying therapies for neurodegenerative diseases including Parkinson's, with lecanemab partnership with Eisai — a regional peer targeting the same indications with biologics approaches.

TypeBroad incumbent
Description

US clinical-stage biotech developing small molecules and biologics for neurodegeneration including Parkinson's and ALS — broader but directly comparable therapeutic-area focus and modality overlap (small molecule CNS).

TypeBroad incumbent
Description

Clinical-stage neuroscience company developing small molecules for Parkinson's disease and other CNS disorders — comparable in modality (small molecule CNS) and indication focus, though at later clinical stage.

TypeDirect peer
Description

Clinical-stage biotech developing pridopidine, a small molecule targeting neurodegenerative diseases including Parkinson's and ALS — comparable as a small-molecule neuroprotective approach for overlapping indications.

TypeBroad incumbent
Description

Acquired by Lilly; develops AAV-based gene therapies for Parkinson's and other neurodegenerative diseases — comparable target indication but different modality (gene therapy vs. small molecule).

TypeDirect peer
Description

Clinical-stage biotech developing neuroprotective small molecules (e.g., NLY01) for Parkinson's and ALS — directly comparable in modality, mechanism (neuroprotection), and indication focus.

TypeOthers
Description

European biotech studio that incubates and co-develops early-stage biotech companies; partnered with GeneCode on the Kevad Bio project — relevant as a partner and indirect comparable in the EU biotech-creation ecosystem.

TypeBroad incumbent
Description

Established US biotech developing antisense oligonucleotide therapies for neurological diseases including Parkinson's and ALS — relevant adjacent player addressing the same disease-modifying neuro indication space.

TypeBroad incumbent
Description

Commercial-stage CNS biotech with zuranolone approved; pursues small-molecule neurotherapeutics — comparable in CNS small-molecule focus, though broader and commercially more mature.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GeneCode AS

Neurodegenerative Disease Therapeuticsgenecode.com

GeneCode AS is an Estonian preclinical-stage pharmaceutical company developing orally bioavailable small-molecule GDNF mimetics for Parkinson's disease, ALS, inflammatory bowel disease, and retinitis pigmentosa. The platform pursues disease-modifying therapies via GFRα1/RET receptor agonism, funded through EU and Estonian grants and targeting future pharma licensing agreements.

What GeneCode AS does

GeneCode AS (legal entity GeneCode Ltd.) is an Estonian preclinical-stage pharmaceutical company headquartered in Tallinn that develops small-molecule drugs designed to activate the GDNF (Glial cell line-Derived Neurotrophic Factor) receptor complex (GFRα1/RET) and thereby protect or restore neurons in neurodegenerative and related diseases. Its science originated in Prof. Mart Saarma's laboratory at the University of Helsinki, where the crystal structure of the GDNF/GFRα1 receptor complex was solved, enabling rational small-molecule design; a proprietary high-throughput luciferase assay was then used to screen over 30,000 compounds from the company's chemical library, yielding lead candidates (including BT13) reported to be more potent than natural GDNF and capable of crossing the blood-brain barrier for oral systemic delivery.

The product portfolio currently comprises a GDNF Mimetics Platform and four indication-targeted drug candidate programs: RET agonists for Parkinson's disease (the primary lead), GDNF mimetics for amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, and inflammatory bowel disease (IBD). Parkinson's disease is the most advanced program, targeting both motor and non-motor symptoms via weekly or less-frequent oral dosing and designed as the first disease-modifying rather than symptomatic therapy. The IP base includes 50+ patent families, and the underlying research is supported by 600+ peer-reviewed publications with 30,000+ citations.

GeneCode generates no commercial product revenue today; its economics rest on non-dilutive grant funding (Enterprise Estonia, Estonian Business and Innovation Agency, EU Regional Development Fund) plus a single €14.3M equity tranche inside the €16M EIC Accelerator award received in 2023. Its go-to-market is event- and partnership-driven — Argobio co-develops the Kevad Bio Parkinson's project, and the company participates in EU forums such as Healthcare Transformation Forum and Medtech Impact 2025 — with the explicit commercial endpoint being licensing or co-development agreements with major pharmaceutical companies for clinical development, regulatory approval, and global commercialization of disease-modifying therapies in Parkinson's disease, ALS, IBD, and retinitis pigmentosa.

GeneCode AS firmographics

Firmographics
Name
GeneCode AS
Legal name
GeneCode Ltd.
Website
https://genecode.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
1–10 employees
Short description
GeneCode AS is an Estonian preclinical-stage pharmaceutical company developing orally bioavailable small-molecule GDNF mimetics for Parkinson's disease, ALS, inflammatory bowel disease, and retinitis pigmentosa. The platform pursues disease-modifying therapies via GFRα1/RET receptor agonism, funded through EU and Estonian grants and targeting future pharma licensing agreements.
Ownership category
akta.pro rank

GeneCode AS industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Small molecule drugs
  • Neurodegenerative disease therapeutics
  • GDNF receptor agonists
  • Pharmaceutical R&D
  • Disease-modifying therapies

Where GeneCode AS is headquartered

Location

Headquarters

HQ city
Tallinn
HQ country
Estonia
HQ region
Europe

Offices1 record

Markets served

GeneCode AS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Drug Development and Licensing: As a preclinical-stage pharmaceutical company, GeneCode is developing small-molecule drugs for neurodegenerative diseases. Revenue will be generated through licensing agreements, co-development partnerships with pharmaceutical companies, and eventual product sales following regulatory approval. The company has received significant grant and equity funding from EU and Estonian sources to advance clinical development.
  2. Government Grants and Non-dilutive Funding: GeneCode has secured multiple grants including €16M from EIC Accelerator (split as €1.7M grant and €14.3M equity), €1.5M from Estonian Business and Innovation Agency, €1.6M from Enterprise Estonia, and €2M R&D Grant from Enterprise Estonia. These grants support preclinical research and IND-enabling studies.

Go-to-market motion2 records

Marketing channels5 records

GeneCode AS product offering

Product offering

Core offering

GeneCode AS is a preclinical-stage pharmaceutical company developing small-molecule drugs that activate GDNF receptors (GFRα1/RET complex) to protect and restore neurons. Its lead program targets disease-modifying treatment of Parkinson's disease via orally bioavailable RET agonists that cross the blood-brain barrier, with additional programs in ALS, inflammatory bowel disease, and retinitis pigmentosa. The company leverages a proprietary GDNF Mimetics Platform built on the resolved crystal structure of the GDNF/GFRα1 receptor complex and high-throughput screening of 30,000+ compounds.

Product overview

GeneCode is a preclinical-stage pharmaceutical company developing a GDNF Mimetics Platform that enables the discovery and development of small molecule drugs targeting GDNF (glial cell line-derived neurotrophic factor) receptors. The company's lead program focuses on RET agonists for Parkinson's disease treatment, with the platform also being applied to develop candidates for ALS, retinitis pigmentosa, and inflammatory bowel disease. The GDNF Mimetics Platform was used to screen over 30,000 compounds, identifying lead candidates now advancing into IND-enabling studies. Key drug candidates include BT13, a novel small molecule GDNF receptor RET agonist.

Differentiator

Problem solved

Functional benefit

Products and services

  • GDNF Mimetics Platform Proprietary drug discovery platform that identifies and develops small molecule compounds activating GDNF receptors (GFRα1/RET complex) to mimic neurotrophic factor activity for treatment of neurodegenerative diseases. Built on the resolved GDNF/GFRα1 receptor crystal structure and a high-throughput luciferase assay screening 30,000+ compounds; for internal pipeline use and partnership with pharmaceutical companies.
  • RET Agonists for Parkinson's Disease Small molecule RET receptor agonists targeting the GFRα1-RET complex for disease-modifying treatment of Parkinson's disease, designed to cross the blood-brain barrier and be administered orally, addressing both motor and non-motor symptoms.
  • GDNF Mimetics for ALS Small molecule GDNF receptor agonist drug candidates being developed as a neuroprotective therapy for amyotrophic lateral sclerosis (ALS), targeting motor neuron survival.
  • GDNF Mimetics for Retinitis Pigmentosa GDNF receptor agonist compounds being explored as a neuroprotective therapy for retinitis pigmentosa, targeting progressive dysfunction of retinal rod and cone photoreceptor cells.
  • GDNF Mimetics for Inflammatory Bowel Disease GDNF receptor agonist compounds being explored for treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis), targeting intestinal epithelium barrier dysfunction.
  • BT13 Compound Novel small molecule GDNF receptor RET agonist discovered by GeneCode, shown to promote neurite growth from sensory neurons and demonstrating neuroprotective effects in Parkinson's disease models.

Quantifiable outcome

  • Neuroprotective effects demonstrated in both animal models of Parkinson's disease and laboratory models using human dopamine neurons
  • +2 more outcomes

Companies that use GeneCode AS

Customer profile

Segments4 records

Ideal customer profiles2 records

GeneCode AS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

GeneCode AS partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ArgobiocoreStrategic or Co-development Partner · 1 December 2021GeneCode partnered with Argobio on Parkinson's Disease research in Argobio's first announced research agreement. The collaboration focuses on the Kevad Bio project developing GDNF mimetics for Parkinson's disease treatment. Argobio is a biotech studio that provides operational support and resources for early-stage biotech companies.
  • University of HelsinkicoreStrategic or Co-development PartnerGeneCode collaborates with the Institute of Biotechnology, HiLIFE, University of Helsinki where Prof. Dr. Mart Saarma serves as research director and professor. The collaboration provides access to cutting-edge neuroscience research and facilities for neurotrophic factor studies.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

GeneCode AS competitors and assessment

Company assessment

Direct peers

  • Herantis Pharma: Finnish clinical-stage biotech developing CDNF (cerebral dopamine neurotrophic factor) protein therapy for Parkinson's disease — directly comparable given GeneCode's co-founder Prof. Saarma's relationship to CDNF and the overlapping neurotrophic factor / Parkinson's disease-modifying mechanism.
  • Prilenia Therapeutics: Clinical-stage biotech developing pridopidine, a small molecule targeting neurodegenerative diseases including Parkinson's and ALS — comparable as a small-molecule neuroprotective approach for overlapping indications.
  • Neuraly (D&D Pharmatech): Clinical-stage biotech developing neuroprotective small molecules (e.g., NLY01) for Parkinson's and ALS — directly comparable in modality, mechanism (neuroprotection), and indication focus.

Regional players

  • BioArctic AB: Swedish biotech developing disease-modifying therapies for neurodegenerative diseases including Parkinson's, with lecanemab partnership with Eisai — a regional peer targeting the same indications with biologics approaches.

Broad incumbents

  • Denali Therapeutics: US clinical-stage biotech developing small molecules and biologics for neurodegeneration including Parkinson's and ALS — broader but directly comparable therapeutic-area focus and modality overlap (small molecule CNS).
  • Cerevel Therapeutics: Clinical-stage neuroscience company developing small molecules for Parkinson's disease and other CNS disorders — comparable in modality (small molecule CNS) and indication focus, though at later clinical stage.
  • Prevail Therapeutics: Acquired by Lilly; develops AAV-based gene therapies for Parkinson's and other neurodegenerative diseases — comparable target indication but different modality (gene therapy vs. small molecule).
  • Ionis Pharmaceuticals: Established US biotech developing antisense oligonucleotide therapies for neurological diseases including Parkinson's and ALS — relevant adjacent player addressing the same disease-modifying neuro indication space.
  • Sage Therapeutics: Commercial-stage CNS biotech with zuranolone approved; pursues small-molecule neurotherapeutics — comparable in CNS small-molecule focus, though broader and commercially more mature.

Others

  • Argobio Studio: European biotech studio that incubates and co-develops early-stage biotech companies; partnered with GeneCode on the Kevad Bio project — relevant as a partner and indirect comparable in the EU biotech-creation ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

GeneCode AS social profiles

Digital presence

GeneCode AS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GeneCode AS leadership team

Management profile

Number of profiles

Profiles9 records

GeneCode AS funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GeneCode AS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneCode AS

What does GeneCode AS do?

GeneCode AS is a preclinical-stage pharmaceutical company developing small-molecule drugs that activate GDNF receptors (GFRα1/RET complex) to protect and restore neurons. Its lead program targets disease-modifying treatment of Parkinson's disease via orally bioavailable RET agonists that cross the blood-brain barrier, with additional programs in ALS, inflammatory bowel disease, and retinitis pigmentosa. The company leverages a proprietary GDNF Mimetics Platform built on the resolved crystal structure of the GDNF/GFRα1 receptor complex and high-throughput screening of 30,000+ compounds.

Is GeneCode AS a public or private company?

GeneCode AS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was GeneCode AS founded?

GeneCode AS was founded in 1998. It employs 1 to 10 people.

Where is GeneCode AS based?

GeneCode AS is headquartered in Tallinn, Estonia, in the Europe region.

How does GeneCode AS make money?

Two revenue lines are on record. Pharmaceutical Drug Development and Licensing is the primary driver. The others are government Grants and Non-dilutive Funding.

Who are GeneCode AS's main competitors?

Direct peers on record are Herantis Pharma, Prilenia Therapeutics and Neuraly (D&D Pharmatech). BioArctic AB is listed as a regional player. Broad incumbents are Denali Therapeutics, Cerevel Therapeutics, Prevail Therapeutics, Ionis Pharmaceuticals and Sage Therapeutics. Argobio Studio is listed as an others.

Does GeneCode AS have an API?

No public API is recorded for GeneCode AS.

What industry is GeneCode AS in?

GeneCode AS's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals